Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Furosemide for Fluid Overload (DIVERSION-HF)
NCT02721511Phase 2Withdrawn
- Start
- May 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furosemide in heart failure (HF). Planned start May 2016; status: withdrawn.
02
Drugs
furosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02721511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721511.